Research

First They Shouted '12,000 Points,' Then They're Heading Toward '7,500 Points'?… Goldman's Sudden U-Turn

Goldman Sachs Lowers KOSPI Target Again… From 9,000 to 7,500 June: 12,000 → October: 9,000 → November: 7,500... A 37.5% Decline "Memory Sector Stock Prices Reflect Excessive Concerns Over a 70% Drop in Next Year's Profits" Maintaining Increased Allocation… “50% Total Return in U.S. Dollars Even Under Conservative Assumptions”

kyoungeun kim
2026-11-19 11:24:07

[Edaily Reporter kyoungeun kim ] Global investment bank Goldman Sachs has lowered its 12-month target for the KOSPI to 7,500. This marks the second downward revision in just over three weeks. However, the firm maintained its previous view that the South Korean stock market has the greatest upside potential in Asia.

<YONHAP PHOTO-2798> 수능일 코스피 상승 출발
    (서울=연합뉴스) 이재희 기자 = 19일 서울 중구 하나은행 본점 딜링룸에서 직원들이 업무를 보고 있다. 이날 코스피는 전장보다 0.45% 오른 5,090.04로 시작했다. 2026.11.19
    scape@yna.co.kr/2026-11-19 10:22:05/
<저작권자 ⓒ 1980-2026 ㈜연합뉴스. 무단 전재 재배포 금지, AI 학습 및 활용 금지>
Employees are working in the trading room at Hana Bank’s headquarters in Jung-gu, Seoul, on the 19th. On that day, the KOSPI opened at 5,090.04, up 0.45% from the previous session. Photo = Yonhap News


According to global financial information provider Investing.com and others on the 19th, Goldman Sachs lowered its 12-month target for the KOSPI by 16.7%, from 9,000 to 7,500, in a report released on the 17th (local time). It maintained its “overweight” investment rating. Goldman Sachs had raised its target to 12,000 on June 3 and maintained it for nearly five months. It then lowered the target to 9,000 on the 25th of last month and has now lowered it once again.

The firm cited the market’s “cautious sentiment” as the reason for the downgrade. The firm believes that despite the strong upward trend in the first half of the year, the market remains hesitant to fully reflect corporate fundamentals in stock prices. Goldman Sachs assessed that the South Korean stock market faced a challenging period in the second half of the year due to high volatility and a slowdown in the pace of earnings forecast revisions. It also cited doubts about how long the memory chip market cycle will last as a factor weighing on the index’s upside.

Earnings momentum outside the semiconductor sector has also slowed. According to the report, the projected earnings per share (EPS) growth rate for companies other than Samsung Electronics and SK Hynix rose from 28% in January to 84% in August, before falling to 81% in November. Next year’s forecast also fell from 20% in July to 15% in October.

However, the firm viewed the market’s pessimism regarding memory semiconductors as excessive. Goldman Sachs stated, “Current stock prices in the South Korean memory semiconductor sector already reflect a scenario in which next year’s earnings consensus (market forecast) is revised downward by 70%,” adding, “Considering companies’ statements that DRAM and High-Bandwidth Memory (HBM) supply is fully booked through 2029, such concerns are excessive.” The firm projected that the memory supply shortage would persist through 2028, or as late as 2030. However, it forecast that the earnings per share (EPS) growth rates for Samsung Electronics and SK Hynix would slow from 64% and 47%, respectively, next year to 5% and 13% by 2028.

They also identified investment opportunities in sectors outside the memory industry, citing that valuations have fallen to historic lows.

The macroeconomic environment was also assessed as favorable. Goldman Sachs economists predicted that while South Korea’s economic growth rate next year would slow compared to this year, it would remain at a robust level, exceeding market forecasts and the long-term potential growth rate.

They also noted that the trend toward resolving the “Korea Discount” (the undervaluation of the Korean stock market) is continuing. They cited next year’s annual general meeting season, expanded shareholder returns, and continued corporate governance reforms as additional catalysts for further gains. They also assessed that the market has not yet fully reflected the benefits of corporate governance improvements. From a supply-and-demand perspective, they expected large-scale share buybacks and light investor positions (stock holdings) to have a favorable impact.

Although the target price was lowered, the expected return was still set high. The 7,500 level corresponds to a 12-month forward price-to-earnings ratio (P/E) of 4.9x and a price-to-book ratio (P/B) of 1.18x. Goldman Sachs analyzed that even at this level, the index remains more than 40% below its fair value. It further projected that “even with conservative valuation assumptions, the 12-month total return in U.S. dollars will reach 50%.”

Differences in outlook among global investment banks are widening. In a report released on the 11th, Morgan Stanley predicted that the KOSPI could surpass 10,000 and stabilize within 3 to 5 years, citing an industrial transition centered on artificial intelligence (AI), defense, and energy, as well as capital market reforms.

Economy

Corporation

IT·Science

Economy

Kaia Chairman: "It’s the 'Golden Time' for K-Blockchain… It Should Be Operated Using a Won-Pegged Stablecoin"

A proposal has been put forward to establish a Korea-led blockchain infrastructure ahead of the institutionalization of won-pegged stablecoins and security token offerings (STOs). The vision calls for…
2026-11-20 14:50:02

Corporation

curacle co., ltd. Files for U.S. Phase 2b Clinical Trial of CU06, an Oral Treatment for Diabetic Macular Edema

curacle co., ltd.(365270)is moving forward with a U.S. Phase 2b clinical trial to develop an oral treatment for diabetic macular edema (DME). The trial will re-evaluate the treatment’s efficacy in pat…
2026-11-20 13:02:02

IT·Science

Aimed Bio Inc.’s ADC Technology Export Shows 60% Response Rate in Phase 1 Clinical Trial… Moving Forward with U.S. Approval Trials

#Aimed Bio Inc.’s antibody-drug conjugate (ADC) “BHV-1530 (AMB302),” which was licensed to U.S.-based Biohaven, has demonstrated initial anticancer efficacy in a Phase 1 clinical trial. Biohaven plans…
2026-11-20 13:07:02